Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 03, 2025 16:05 ET | Source: Abivax

Abivax Announces Patient-Reported Outcomes Data from the Phase 3 ABTECT Induction Trials of Obefazimod, Demonstrating Significant Improvements in Quality of Life for Patients with Moderate-to-Severely Active Ulcerative Colitis

Abivax Announces Patient-Reported Outcomes Data from the Phase 3 ABTECT Induction Trials of Obefazimod, Demonstrating Significant Improvements in Quality of Life for Patients with Moderate-to-Severely...
October 24, 2025 08:02 ET | Source: Janssen Cilag International NV

TREMFYA® (guselkumab) receives European Commission approval for subcutaneous induction through to maintenance in adults with ulcerative colitis, now the first IL-23 inhibitor with a fully subcutaneous dose regimen

Guselkumab offers the flexibility of self-administration from the start of treatment in both ulcerative colitis (UC) and Crohn’s disease (CD),1,2,3 providing the simplicity of a fully subcutaneous...
September 29, 2025 16:05 ET | Source: Abivax

Abivax Announces Acceptance of Additional Late-Breaking Abstract from the ABTECT Phase 3 Induction Trials to be Presented at 2025 United European Gastroenterology (UEG) Meeting

Abivax Announces Acceptance of AdditionalLate-Breaking Abstract from the ABTECT Phase 3 Induction Trials to be Presented at 2025 United European Gastroenterology (UEG) Meeting Late Breaking Abstract...
September 22, 2025 10:36 ET | Source: Research and Markets

Gastroenterology - Global Strategic Business Report 2025 Featuring Analysis of 41 Industry Players

Dublin, Sept. 22, 2025 (GLOBE NEWSWIRE) -- The "Gastroenterology - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering.The global market for Gastroenterology was...
September 19, 2025 10:10 ET | Source: Janssen Cilag International NV

TREMFYA (guselkumab) receives positive CHMP opinion for subcutaneous induction regimen in ulcerative colitis, a first for an IL-23 inhibitor

Recommendation based on the findings from the Phase 3 ASTRO study in ulcerative colitis.1,2,3 Guselkumab has the potential to become the first IL-23 inhibitor to offer both subcutaneous and...
September 08, 2025 16:00 ET | Source: Abivax

Abivax Presents First Half 2025 Financial Results

Abivax Presents First Half 2025 Financial Results PARIS, France, September 8, 2025, 10:00 p.m. CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq – ABVX) (“Abivax” or the “Company”), a...
August 26, 2025 09:58 ET | Source: Spherix Global Insights

Patient-Led Decisions Accelerate IBD Treatment Switching, Spherix Global Insights Finds

EXTON, PA, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Patients with inflammatory bowel disease (IBD) in the US are taking a more active role than ever before in the decision to switch their advanced...
July 31, 2025 08:45 ET | Source: Palisade Bio, Inc.

Palisade Bio Receives Notice of Allowance for Composition of Matter Patent Covering Lead Product Candidate PALI-2108 in China

PALI-2108 is the first and only PDE4 inhibitor designed to target terminal ileum and colon for fibrostenotic Crohn’s disease (FSCD) and ulcerative colitis (UC), to address significant unmet medical...
July 30, 2025 04:10 ET | Source: Dr. Falk Pharma

Dr. Falk Pharma und Allianthera (Suzhou) Biopharmaceuticals gehen strategische Partnerschaft für die Entwicklung eines neuartigen AhR-Agonisten ein

Freiburg (Deutschland), Suzhou (China) und Boston (USA), 30. Juli 2025: Dr. Falk Pharma GmbH und Allianthera (Suzhou) Biopharmaceuticals Co., Ltd. geben strategische Partnerschaft für die...
July 30, 2025 04:10 ET | Source: Dr. Falk Pharma

Dr. Falk Pharma and Allianthera (Suzhou) Biopharmaceuticals Forge Strategic Partnership for Novel AhR Agonist Development

Freiburg (Germany), Suzhou (China) and Boston (USA), July 30, 2025: Dr. Falk Pharma GmbH and Allianthera (Suzhou) Biopharmaceuticals Co., Ltd. Announce Strategic Partnership to Develop a Novel AhR...